Intrexon (NASDAQ:XON) Shares Up 6.5%

Shares of Intrexon Corp (NASDAQ:XON) shot up 6.5% during trading on Tuesday . The stock traded as high as $7.28 and last traded at $7.19, 1,780,141 shares traded hands during mid-day trading. An increase of 25% from the average session volume of 1,420,727 shares. The stock had previously closed at $6.75.

Separately, BidaskClub upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $17.00.

The company has a market cap of $1.12 billion, a price-to-earnings ratio of -5.25 and a beta of 2.26. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.97. The company’s 50 day moving average price is $5.86 and its 200 day moving average price is $6.24.

Intrexon (NASDAQ:XON) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. Intrexon had a negative net margin of 393.13% and a negative return on equity of 45.51%. The company had revenue of $23.04 million during the quarter, compared to analysts’ expectations of $32.16 million. Sell-side analysts predict that Intrexon Corp will post -0.96 earnings per share for the current year.

In related news, insider Donald P. Lehr sold 4,830 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $5.60, for a total value of $27,048.00. Following the completion of the sale, the insider now owns 81,156 shares in the company, valued at $454,473.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Thomas Bostick sold 6,533 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $5.83, for a total transaction of $38,087.39. Following the completion of the sale, the chief operating officer now owns 80,813 shares of the company’s stock, valued at approximately $471,139.79. The disclosure for this sale can be found here. Insiders sold 37,066 shares of company stock valued at $213,533 in the last quarter. Company insiders own 44.00% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in Intrexon during the third quarter worth about $63,000. Susquehanna Fundamental Investments LLC acquired a new position in Intrexon during the second quarter worth about $115,000. Man Group plc acquired a new position in Intrexon during the second quarter worth about $143,000. LPL Financial LLC raised its position in Intrexon by 15.8% during the second quarter. LPL Financial LLC now owns 19,494 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 2,659 shares during the last quarter. Finally, Jefferies Group LLC acquired a new position in Intrexon during the second quarter worth about $197,000. Hedge funds and other institutional investors own 76.33% of the company’s stock.

Intrexon Company Profile (NASDAQ:XON)

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Read More: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.